Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?

Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?

There is sparse literature demonstrating effective treatments for metastatic chromophobe renal cell carcinoma (ChRCC). The tyrosine kinase inhibitor (TKI) sunitinib selectively inhibits the VEGF pathway and it is a standard care for metastatic clear cell renal cell carcinoma (ccRCC), although data s...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Jacob W. Bruinius, Karl J. Dykema, Sabrina L. Noyes, Bin Tean Teh, Brian R. Lane
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Wiley 2019-01-01
Saila:Case Reports in Urology
Sarrera elektronikoa:http://dx.doi.org/10.1155/2019/2479823

Internet

http://dx.doi.org/10.1155/2019/2479823

Antzeko izenburuak